Jump to content
  • Forum Statistics

    • Total Topics
    • Total Posts
  • The Rosacea Research & Development Institute [RRDi] is the first 501 (c) (3) non profit organization approved by the IRS established June 7, 2004 in the State of Hawaii, USA for the purpose of finding a cure for rosacea, researching rosacea, and to form a rosacea patient advocacy organization established by volunteer rosaceans for rosacea sufferers. In December 2019 we have moved the corporate office to the State of Alabama and have registered as a non profit corporation.

    Our non profit organization for rosacea patient advocacy web site is a digital data repository of rosacea information that can serve you personally as an armamentarium of rosacea treatment options. We have tools to help you in your search for a cure to rosacea, or at least a way to control it.

    We have chosen the Invision Community as the chief digital platform tool (with beta versions for Android and iOS mobile apps) to use, a public platform for guests and inactive members. Our member forum is the most private forum for rosacea on the internet. We also have a private platform using Tapatalk using our rosacea-control.com domain. 

    We are rosacea sufferers [rosaceans] and all are volunteers. We rely on donations. No one is receiving a salary or getting paid. We don't spend donated funds on private contractors that are owned by any member of the board of directors. We do not spend donated funds so our members can attend dermatology conventions. All donations are spent on keeping this non profit organization for rosacea sufferers a viable patient advocacy organization and our rules state that 'members may not profit from the institute' (rule number 3). Read our mission statement

    No one has a paid salary, we pay NO private contractors nor do we use donations so our members can attend dermatology conventions. 

    All the other rosacea non profits are not run by rosacea sufferers (see Other Non Profit Rosacea Organizations on this page). Check out the other non profit organizations for rosacea, discover for yourself and you will find out who serve on the board of directors (non rosaceans - dermatologists/businessmen) and then simply follow the money (what does the organization spend most of the donated money on?) and discover for yourself that the other non profit organizations for rosacea spend most of the donations on (1) private contractors, (2) dermatologist member conventions or (3) salaries. We have no special interest other than finding the cure for rosacea and forming a rosacea patient advocacy organization. Our non profit has no salaries, no spending on private contractors, no expenses for member conventions. Follow the money (this is where we spend our money). Notice where most of the money is spent with another rosacea non profit, who has spent millions of dollars on private contractors owned by the president of the non profit and only 10% on rosacea research. 

    Read our Misson Statement and see if you agree? If you suffer from rosacea, this is the rosacea non profit to join. Your membership increases our impact on the medical community. Our goal is to reach 10,000 members. Please join and help us reach our goal. What if 10,000 members got together and each donated one dollar and all the members agreed we should sponsor a certain rosacea research study. Is this possible? Only with your help. 

    You may want to read our post about Anonymity, Transparency and Posting before joining. We have now switched to a subscription member service

    The logo of the RRDi includes a butterfly because rosacea typically manifests itself in a facial butterfly formation, however the irony of the butterfly effect is apropros. Learn More.

    You may want to learn about the history of this non profit or why it was formed

    If you are a rosacean, volunteer by joining our private member forum and posting or in our public guest forum (registration required) becoming a part of 'finding the cure' for rosacea if you join. Our goal is 10,000 members. Membership is free. You can help us reach our goal by joining with just your email address.  if privacy is of paramount importance to you use Sign in with Apple and join our private member forum. Or you can simply browse our web site and guest forum for free. Our non profit affiliate store is another source of rosacea treatment options. 

    If you want to post about your rosacea, we certainly allow you to post feedback in our GUEST forum or register an account in our member forum, i.e,, in our public community support, and, if you want to learn about and treat your rosacea, this is the best non profit organization for rosacea sufferers. At the social networks like Facebook, Instagram or Reddit can you find the incredible digital tools the RRDi provides free to its members or the ability to find what you are searching for in rosacea research? Are you able through such social media groups to influence the medical community how you feel about rosacea? Read our mission statement and compare with your private rosacea social media group, i.e., like Facebook, Instagram or Reddit.  

    The RRDi is registered at GuideStar and Trustpilot • Write a Review of Our Non Profit

  • Member Statistics

    Total Members
    Most Online
    Richard Trafford-Owen
    Newest Member
    Richard Trafford-Owen

  • Registered with the USA Internal Revenue Service


    EIN 20-1259275

  • 240px-Seal_of_Alabama.svg.png

  • Alabama Secretary of State Certification

    Entity Identification Number 596-247

  • Posts

    • Dermatol Pract Concept. 2023 Jul 1;13(3). doi: 10.5826/dpc.1303a182. ABSTRACT INTRODUCTION: Few studies have evaluated the histopathological characteristics of clinical rosacea subtypes in detail. OBJECTIVES: To assess rosacea histopathological features in correspondence to clinical subgroups. METHODS: The histopathological findings of 204 rosacea patients were analyzed retrospectively and were compared among clinical subtypes. RESULTS: Thirt-Two Percent of patients were male and 68% were female. Seventy-three patients had erythematotelangiectatic rosacea (ETR) and 110 had papulopustular rosacea (PPR), 12 were ETR + PPR, 4 ocular, 2 phymatous, and 3 had Morbihan's edema. Perivascular and perifollicular lymphohistiocytic infiltration, perifollicular exocytosis, follicular spongiosis, and ectatic vessels were almost found in all subtypes. Solar elastosis was higher in ETR. Spongiosis, exocytosis of inflammatory cells into epidermis, acanthosis, and granulomatous reaction were higher in PPR. Inflammatory cells exocytosis was more in PPR and phymatous. Demodex folliculorum was identified in 27% of ETR, 33.6% of PPR, 50% of phymatous, one ocular patient, and none of Morbihan edema. Demodex brevis were found in 5% of ETR, 3% of PPR, and 50% of phymatous. Demodex brevis not folliculorum was more in phymatous. Spongiosis was the most common finding in ocular rosacea. CONCLUSIONS: Spongiosis, exocytosis of inflammatory cells, and granulomatous reactions were more in PPR. Solar elastosis was more in ETR. Histopathological findings were compatible with clinical subgroups. PMID:37557115 | DOI:10.5826/dpc.1303a182 {url} = URL to article
    • Dermatol Pract Concept. 2023 Jul 1;13(3). doi: 10.5826/dpc.1303a168. ABSTRACT INTRODUCTION: Studies have suggested that botulinum toxin A may improve skin quality, and application protocols using hyper-diluted doses of botulinum toxin (microdosing) have been studied as a way to achieve therapeutic goals without fully paralyzing the targeted muscles. OBJECTIVES: To evaluate the effects of a combined protocol utilizing both the standard dosing and the microdosing of AbobotulinumtoxinA for the improvement of skin quality, measured by objective and subjective measurements. METHODS: Thirty patients were treated with botulinum toxin using both the standard technique and the microdosing technique. Objective (Sebumeter®, Mexameter® and digital dermoscopy pictures) and subjective (Global Aesthetic Improvement Scale and a clinical scale for evaluating the quality of facial skin) measurements of the effects in the treated areas were taken to assess the efficacy of the treatment. RESULTS: Digital dermoscopy showed a marked reduction of erythema and telangiectasias. Erythema and telangiectasias improved both on objective and subjective measurements. Skin oleosity, static rhytids, papules and pustules and enlarged pores improved on subjective measurements. Patient satisfaction was high (93%) despite the high rate of adverse events (56%). CONCLUSIONS: The combined application of standard doses and microdoses of AbobotulinumtoxinA is effective in improving the overall quality of facial skin. The effects on erythema and telangiectasias suggest that it is an effective treatment option for patients with erythematotelangiectatic rosacea. When applying microdoses of botulinum toxin in the lower and mid-face, the doses and pattern of injection should be customized for each patient to reduce the occurrence of adverse events. PMID:37557136 | DOI:10.5826/dpc.1303a168 {url} = URL to article
    • Dermatol Pract Concept. 2023 Jul 1;13(3). doi: 10.5826/dpc.1303a131. ABSTRACT INTRODUCTION: Superficial folliculitis of the scalp (SFS) is a common complaint in clinical practice, and initial presentation may be difficult to differentiate as they may appear very similar to each other. OBJECTIVES: The aim of this thesis is to describe the pathologies that occur clinically as folliculitis of the scalp, identify their causes and characteristics and create a standardized classification. METHODS: This is a retrospective clinical, dermoscopic and histopathological study over 10 years of dermatologic consultations. Only individuals with a confirmed diagnosis of SFS (updated diagnostic criteria or biopsy) were included. RESULTS: In this review, we describe the various clinical features of different causes of SFS in ninety-nine cases and divided into infectious due to fungus, bacteria, or virus and inflammatory conditions such as rosacea, acneiform eruption and Ofuji syndrome. CONCLUSIONS: The clinician must differentiate SFS from other underlying scarring disorders to prevent poorer outcomes. We created an algorithm to help the clinician reach a proper diagnosis. PMID:37557142 | DOI:10.5826/dpc.1303a131 {url} = URL to article
    • J Drugs Dermatol. 2023 Aug 1;22(8):838-839. doi: 10.36849/jdd.7103. ABSTRACT Improved patient-physician relationships (PPR) are associated with better patient satisfaction and disease outcomes, however, there is limited literature assessing how PPR affects adherence in dermatology. We recruited 30 subjects with a clinical diagnosis of rosacea. Subjects were instructed to use ivermectin 1% cream once daily for 3 months and adherence was measured using the Medication Event Monitoring System cap. The Patient-Doctor Relationship Questionnaire (PDRQ-9), a validated questionnaire assessing patients’ perceived strength of the relationship with their doctor, was completed. Mean adherence for all subjects over three months of the study was 62%. PDRQ-9 scores positively correlated with adherence rates for 3 months of treatment (r(26)=0.52; P=0.006). The perceived strength of the PPR may have a role in patients’ adherence to their medications. Improving the PPR, through empathy and effective communication, may facilitate better medication adherence and treatment outcomes. Perche PO, Singh R, Cook MK, et al. The patient-physician relationship and adherence: observations from a clinical study. J Drugs Dermatol. 2023;22(8):838-839. doi:10.36849/JDD.7103. PMID:37556519 | DOI:10.36849/jdd.7103 {url} = URL to article
    • JAAD Case Rep. 2023 Jun 29;39:14-16. doi: 10.1016/j.jdcr.2023.06.028. eCollection 2023 Sep. NO ABSTRACT PMID:37554359 | PMC:PMC10404599 | DOI:10.1016/j.jdcr.2023.06.028 {url} = URL to article
    • Eur J Pediatr. 2023 Aug 9. doi: 10.1007/s00431-023-05083-0. Online ahead of print. ABSTRACT Rosacea is a facial inflammatory disorder that shows an increasing incidence with age. While rosacea is common > 60 years of age, pediatric rosacea is uncommon. Diagnostic criteria are based on clinical symptoms. Laboratory investigations and histopathology are only needed to exclude other differential diagnoses. There are several subtypes such as erythemato-telangiectatic, papulo-pustular, periorificial, and granulomatous variants. In contrast to adult rosacea, phymatous subtypes do not belong to pediatric rosacea. A special subtype seen in infants and children is an idiopathic facial aseptic granuloma. Genetic and environmental factors contribute to its pathogenesis. Treatment options are in analogy to adult rosacea classified into topical and systemic drugs. In the case of oral tetracyclines, discoloration of teeth and impairment of enamel are possible adverse events. CONCLUSION: Pediatric rosacea belongs to the rosacea spectrum but has peculiarities compared to the adult subtype. WHAT IS KNOWN: • Rosacea is a chronic inflammatory disorder different from acne. • Rosacea gets more common with advanced age. WHAT IS NEW: • Pediatric rosacea is an uncommon subtype with peculiar clinical presentation. • Demodicosis is very rare in immunocompetent children. PMID:37555972 | DOI:10.1007/s00431-023-05083-0 {url} = URL to article
    • J Cosmet Dermatol. 2023 Aug 7. doi: 10.1111/jocd.15923. Online ahead of print. ABSTRACT BACKGROUND: Topical azelaic acid (AA) is indicated for acne and rosacea, but there is some evidence for its use for other dermatological conditions. AIMS: To assess the effectiveness and safety of topical AA for acne vulgaris, rosacea, hyperpigmentation/melasma, and skin aging. METHODS: RCTs of at least 6 weeks' treatment duration were eligible for inclusion. Databases including MEDLINE, Embase, CINAHL, and ClinicalTrials.gov were searched up to December 2022. Two reviewers were involved in all stages of the systematic review process. RESULTS: Forty-three RCTs met the inclusion criteria. Meta-analyses within 20 rosacea studies demonstrated that erythema severity, inflammatory lesion counts, overall improvement, and treatment success (achieving skin clarity) were significantly improved with AA compared with vehicle after 12 weeks. AA was more effective than metronidazole 0.75% for improved erythema severity, overall improvement, and inflammatory lesion counts. Sixteen acne studies suggest that AA is more effective than vehicle for improving global assessments and reducing acne severity. AA 20% also significantly reduced more lesions than erythromycin gel. Within seven melasma studies, AA 20% was significantly better than vehicle for both severity and global improvement. AA 20% demonstrated significantly better results compared with hydroquinone 2% for global improvement. Very few significant differences between AA and comparators were observed for commonly reported adverse events. No eligible RCTs were found that evaluated skin aging. CONCLUSIONS: AA is more effective than vehicle for rosacea, acne and melasma. Comparisons between AA and other treatments were often equivalent. Where there is equivalence, AA may be a good option for some clinical situations. RCT evidence is needed to evaluate the effectiveness of AA on skin aging. PMID:37550898 | DOI:10.1111/jocd.15923 {url} = URL to article
    • Clin Cosmet Investig Dermatol. 2023 Jul 25;16:1949-1954. doi: 10.2147/CCID.S417070. eCollection 2023. ABSTRACT Morbihan disease is a rare entity involving the upper two-thirds of the face and characterized by chronic erythematous edema, which is recalcitrant to the traditional therapy of rosacea. We report a case of Morbihan disease effectively treated with macro-focused high-intensity focus ultrasound (MF-HIFU). After MF-HIFU treatment, an obvious reduction in swelling was observed with decreased erythema and hyperalgesia. In addition, in-vitro experiments were conducted to measure the actual temperature of the skin tissue under the epidermis. The results of the in-vitro experiments showed that the temperature plateau in the skin sample was reached at approximately 42°C after 5-min treatment or longer. MF-HIFU might be a promising energy-based therapy for Morbihan disease. PMID:37519942 | PMC:PMC10386836 | DOI:10.2147/CCID.S417070 {url} = URL to article
    • Skin Res Technol. 2023 Jul;29(7):e13409. doi: 10.1111/srt.13409. NO ABSTRACT PMID:37522510 | DOI:10.1111/srt.13409 {url} = URL to article
  • Create New...

Important Information

Terms of Use